Fjarde AP Fonden Fourth Swedish National Pension Fund Reduces Stake in Mylan NV (MYL)

Fjarde AP Fonden Fourth Swedish National Pension Fund lowered its position in shares of Mylan NV (NASDAQ:MYL) by 5.8% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 135,822 shares of the company’s stock after selling 8,422 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Mylan were worth $4,971,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of MYL. First Mercantile Trust Co. acquired a new position in Mylan in the second quarter valued at about $121,000. Stratos Wealth Partners LTD. acquired a new position in Mylan in the third quarter valued at about $183,000. FTB Advisors Inc. acquired a new position in Mylan in the second quarter valued at about $188,000. Reilly Financial Advisors LLC raised its stake in Mylan by 69.4% in the third quarter. Reilly Financial Advisors LLC now owns 5,217 shares of the company’s stock valued at $191,000 after purchasing an additional 2,137 shares in the last quarter. Finally, BB&T Corp acquired a new position in Mylan in the third quarter valued at about $202,000. 81.91% of the stock is owned by institutional investors.

A number of research firms recently commented on MYL. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $41.00 price target on shares of Mylan in a research note on Tuesday, November 20th. Morgan Stanley cut Mylan from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $46.00 to $36.00 in a research report on Tuesday, October 9th. JPMorgan Chase & Co. set a $45.00 target price on Mylan and gave the company a “buy” rating in a research report on Tuesday, November 6th. Raymond James cut Mylan from a “strong-buy” rating to an “outperform” rating in a research report on Thursday, August 9th. Finally, Royal Bank of Canada upgraded Mylan from a “sector perform” rating to an “outperform” rating and set a $53.00 target price on the stock in a research report on Monday, August 13th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $46.56.

Mylan stock opened at $33.49 on Friday. The stock has a market capitalization of $17.21 billion, a price-to-earnings ratio of 7.34, a price-to-earnings-growth ratio of 1.10 and a beta of 1.53. The company has a current ratio of 1.26, a quick ratio of 0.77 and a debt-to-equity ratio of 1.20. Mylan NV has a 12-month low of $30.33 and a 12-month high of $47.82.

Mylan (NASDAQ:MYL) last released its quarterly earnings results on Monday, November 5th. The company reported $1.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.19 by $0.06. The company had revenue of $2.86 billion for the quarter, compared to analysts’ expectations of $2.91 billion. Mylan had a return on equity of 19.39% and a net margin of 4.71%. The business’s quarterly revenue was down 4.2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.10 earnings per share. As a group, equities analysts anticipate that Mylan NV will post 4.66 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.wkrb13.com/2018/11/25/fjarde-ap-fonden-fourth-swedish-national-pension-fund-reduces-stake-in-mylan-nv-myl.html.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Featured Story: Fundamental Analysis – How It Helps Investors

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply